



ResMed Inc. (RMD)

Updated November 13th, 2020 by Jonathan Weber

Key Metrics

Current Price:	\$213	5 Year CAGR Estimate:	0.8%	Market Cap:	\$31B
Fair Value Price:	\$120	5 Year Growth Estimate:	12.0%	Ex-Dividend Date:	11/10/20
% Fair Value:	178%	5 Year Valuation Multiple Estimate:	-10.9%	Dividend Payment Date:	12/17/20
Dividend Yield:	0.7%	5 Year Price Target	\$211	Years Of Dividend Growth:	8
Dividend Risk Score:	B	Retirement Suitability Score:	D	Last Dividend Increase:	5.4%

Overview & Current Events

ResMed is a medical devices company that engages in the development, manufacturing and marketing of devices that diagnose, treat and manage a range of respiratory disorders such as sleep apnea. The company was founded in 1989 and is headquartered in San Diego, CA.

ResMed reported its first quarter (fiscal 2021) earnings results on October 29. The company reported revenues of \$750 million for the quarter, which represents an increase of 10% compared to the prior year's quarter. At constant currency rates, ResMed would have been able to grow its revenues by 9%. ResMed's software as a service business grew at a pace of 6% year-over-year. This business unit is quite young and not very large, which is why the majority of company-wide revenue growth is generated in other business units. ResMed was able to grow its margins further, the company boosted its adjusted gross margin by another 30 basis points during the quarter.

ResMed generated earnings-per-share of \$1.27 during the first quarter, which beat analyst estimates easily, by \$0.24. ResMed's earnings-per-share were up by a massive 37% compared to the prior year's quarter. ResMed was able to generate cash flows from operations of \$144 million for the quarter, which was down sequentially.

Growth on a Per-Share Basis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
EPS	\$1.44	\$1.71	\$2.10	\$2.39	\$2.47	\$2.49	\$2.82	\$3.53	\$3.64	\$4.76	\$5.20	\$9.16
DPS	---	---	\$0.68	\$1.00	\$1.12	\$1.20	\$1.32	\$1.40	\$1.48	\$1.56	\$1.56	\$2.51
Shares¹	152	142	142	140	141	141	142	143	143	143	142	140

ResMed has been a reliable growth investment in the past. The company produced a very compelling 15% earnings-per-share growth rate through the last decade and was not impacted by the last financial crisis.

ResMed's strong growth rate was possible through a combination of revenue increases, some margin expansion, and a declining share count. Revenue growth was the most important factor, which ResMed achieved through growing its product portfolio, as well as via geographic expansion. Through focused R&D, ResMed was able to establish itself as the global leader in sleep apnea management, an indication with a large market that is still severely underpenetrated. Studies show that up to one-fourth of adults have sleep apnea. In many major markets market penetration is still below 10%, which is why ResMed has a lot of potential to grow its revenues going forward, even without expanding its product lineup. All that is required will be investments into sales & marketing and additional manufacturing capacity.

Chronic obstructive pulmonary disease (COPD) is another indication with need for treatment where ResMed is establishing itself. ResMed is also actively working at the intermixture between medtech and information technology by investing heavily into connected health solutions, as this is deemed a major growth market over the coming decades. ResMed's offerings include end-to-end systems for sleep and respiratory care and cloud-based diagnostic testing.

ResMed is active in attractive markets and growth is unlikely to slow down going forward. On top of that, ResMed is not impacted by the current coronavirus crisis, as demand for its offerings does not depend on economic growth.

¹ In Millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



ResMed Inc. (RMD)

Updated November 13th, 2020 by Jonathan Weber

Valuation Analysis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Now	2026
Avg. P/E	22.3	17.2	20.0	20.3	23.4	22.7	26.1	29.2	34.1	40.3	41.0	23.0
Avg. Yld.	---	---	1.6%	2.1%	1.9%	2.1%	2.0%	1.3%	1.2%	0.8%	0.7%	1.2%

ResMed is a high-quality company with a compelling earnings growth track record, and the earnings growth outlook over the coming years is positive as well. This justifies an above-average valuation multiple, which is why shares were valued at more than 20 times profits throughout most of the last decade. We see a fair value of 23 times net profits, but shares trade massively above that level right now, which is why the stock looks severely overvalued today.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
Payout	---	---	32.4%	41.8%	45.3%	48.2%	46.8%	39.7%	38.5%	32.8%	30.0%	27.4%


ResMed only started paying dividends in 2013, but since then the dividend has grown consistently. The most recent dividend increase of 5% was below the average dividend growth rate over the last couple of years. Due to a relatively low dividend payout ratio of just 30%, the dividend looks very safe, we believe.

ResMed is smaller than many of its medtech peers, but it is very well positioned in the niche it addresses, and it owns strong products and a respectable IP portfolio. We believe that ResMed will continue to be a dominant player in the markets that it targets; competition does not seem to be a problem. The company's products are needed whether the economy is doing well or not, which is why ResMed is not a cyclical company. The company's earnings-per-share continued to grow through the Great Recession, and this will most likely be the case during future recessions as well.

Final Thoughts & Recommendation

ResMed is a high-quality medtech company that targets an attractive market and that has achieved compelling earnings growth rates in the past. We believe that ResMed will be able to grow profitably during the coming years as well, and the company will also continue to grow its dividend. Shares trade significantly above our fair value estimate, however, which is why we rate ResMed a sell, even though the company looks strong on a fundamental basis.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



ResMed Inc. (RMD)

Updated November 13th, 2020 by Jonathan Weber

Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Revenue	1,243	1,369	1,514	1,555	1,679	1,839	2,067	2,340	2,607	2,957
Gross Profit	741	821	941	990	1,011	1,066	1,202	1,335	1,494	1,718
Gross Margin	59.6%	60.0%	62.1%	63.7%	60.2%	58.0%	58.1%	57.0%	57.3%	58.1%
SG&A Exp.	372	403	431	450	479	488	554	600	645	677
D&A Exp.	71	86	78	73	73	87	112	120	151	181
Operating Profit	267	294	355	411	409	436	457	560	636	809
Operating Margin	21.5%	21.5%	23.4%	26.5%	24.4%	23.7%	22.1%	23.9%	24.4%	27.4%
Net Profit	227	255	307	345	353	352	342	316	405	622
Net Margin	18.3%	18.6%	20.3%	22.2%	21.0%	19.2%	16.6%	13.5%	15.5%	21.0%
Free Cash Flow	210	322	331	310	311	480	343	434	382	696
Income Tax	77	77	78	86	83	87	76	206	114	111

Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Assets	2,069	2,138	2,211	2,361	2,182	3,257	3,468	3,064	4,108	4,587
Cash & Equivalents	735	810	876	906	717	731	822	189	147	463
Accounts Receivable	274	283	318	360	363	382	451	484	528	475
Inventories	201	174	146	165	247	224	268	269	350	417
Goodwill & Int. Ass.	283	311	324	335	311	1,359	1,327	1,284	2,378	2,338
Total Liabilities	338	530	600	603	594	1,562	1,508	1,005	2,035	2,090
Accounts Payable	55	55	61	85	81	93	93	93	116	136
Long-Term Debt	100	251	301	301	301	1,173	1,079	281	1,271	1,176
Shareholder's Equity	1,731	1,608	1,611	1,758	1,587	1,695	1,960	2,059	2,072	2,497
D/E Ratio	0.06	0.16	0.19	0.17	0.19	0.69	0.55	0.14	0.61	0.47

Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Return on Assets	12.3%	12.1%	14.1%	15.1%	15.5%	13.0%	10.2%	9.7%	11.3%	14.3%
Return on Equity	15.0%	15.3%	19.1%	20.5%	21.1%	21.5%	18.7%	15.7%	19.6%	27.2%
ROIC	14.0%	13.8%	16.3%	17.4%	17.9%	14.8%	11.6%	11.7%	14.2%	17.7%
Shares Out.	152	142	142	140	141	141	142	143	143	143
Revenue/Share	7.91	9.17	10.34	10.77	11.77	12.98	14.51	16.25	18.04	20.30
FCF/Share	1.34	2.16	2.26	2.15	2.18	3.39	2.40	3.01	2.64	4.78

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.